Nanolyze receives 2 MSEK Vinnova grant for powering nanomedicine research with AI

..............................................................

GU Ventures share news and information about the business, its companies, and alumni companies.

..............................................................

In collaboration with AstraZeneca and Chalmers Industriteknik, Nanolyze will power their technology with AI to improve performance and ease of use. This will broaden the spectrum of researchers in pharmaceutical companies who can make use of the Nanolyze technology to speed up development processes and to develop more efficient and precise therapies based on the emerging field of nanomedicine. The initiation of this project is a direct result of Nanolyze being strategically located within the AstraZeneca BioVentureHub.

Cures for currently uncurable diseases like Alzheimer’s and many forms of cancers may be found using powerful technologies based on nanoparticles delivering medicine directly into our cells. A major hurdle blocking the advancement is the low delivery efficiency of around 1%. To achieve better precision and efficiency, better analysis tools are required to be able to predict function. Nanolyze fills unique gaps in the analysis chain already today, but increased sensitivity using machine learning (a subset of AI), which is the main goal of this project, will hopefully enable a paradigm shift in research applications as well as in production control.

Researchers who have access to the Nanolyze instrument can, at an early stage, better predict performance in later in vitro experimental phases. This will allow for a reduced number of expensive cell studies and shorten the development loops. The extension of this is faster access for humanity to novel treatments with less side effects and an increased delivery rate. To consider nanomedicine for therapeutic applications in cancer, it is likely a need for a delivery efficacy of around 10-20%.

“We are happy and proud to collaborate with Nanolyze on this innovative and important project. We see that the results from this project could have great impact in the field of nanomedicine research and quality control.“ , says Kent Rundgren, Innovation Manager at Chalmers Industriteknik

“With this funding and the power of a great collaboration with the AstraZeneca AI team and Chalmers Industriteknik, we can reach a larger spectrum of users and applications. We aim to be able to include an increased range of particles that are possible to analyze, improve precision, and decrease the need for user interaction. The project shows the impact of symbiosis offered by the BioVentureHub, which provides access to the diverse and multifaceted network of expertise existing within a large company with a strong dare-to-share culture”, says Nils Löfgren, CEO at Nanolyze

See LinkedIn post here: https://www.linkedin.com/posts...